Butterfly Network (BFLY) Q2 2026 earnings review
Record Revenue and Margins Indicate the Pivot is Working
Butterfly Network posted a blowout quarter, validating its transition from a pure medical hardware vendor to a diversified semiconductor and AI platform. Revenue surged 39% YoY to $32.6M, crushing expectations. More importantly, the high-margin Butterfly Embedded licensing business drove gross margins to a record 71.4%, pulling Adjusted EBITDA loss to within striking distance of breakeven (-$1.4M). Management confidently raised full-year guidance, though a weak international segment and a sequential step-down in Q3 profitability guidance suggest the path forward won't be entirely linear.
🐂 Bull Case
Gross margins expanded 770 bps YoY to 71.4%. The company is successfully layering high-margin Butterfly Embedded licensing fees on top of its core hardware sales, fundamentally altering its unit economics.
The Home & Community Care business is moving from pilot to commercialization in H2 2026, while the Embedded portfolio expanded to 11 partners, including major players like Midjourney and Aleph Neuro.
🐻 Bear Case
While the U.S. soared 57% YoY, International sales dropped 14%. If the global distributor network continues to weaken, it will drag on total volume growth.
Operating expenses rose 19% YoY to $37.0M. Management must prove they can scale the new Embedded and Home Care lines without proportionally scaling headcount.
⚖️ Verdict: 🟢
Bullish. The 78% improvement in Adjusted EBITDA loss and 39% revenue growth demonstrate that Butterfly's "Ultrasound-on-Chip" platform holds significant monetization power outside traditional hospital channels.
Key Themes
Butterfly Embedded is Transforming the Business Model
The company's strategic pivot to license its Ultrasound-on-Chip platform is paying massive dividends. Driven by partnerships with Midjourney and new addition Aleph Neuro, the Embedded segment's high-margin return was the primary catalyst for gross margin leaping from 63.7% to 71.4%. This division shifts Butterfly away from a low-margin hardware grind into high-margin tech licensing.
Enterprise and Government Software Momentum
The core POCUS business is building structural moats. Butterfly secured provisional authorization from the VA and is on track for FedRAMP certification in Q3 2026. Furthermore, they signed six new enterprise software agreements for Compass AI, significantly boosting the recurring software pipeline.
Home & Community Care Commercialization
Following successful pilots that reduced hospital readmissions, the Home & Community Care initiative is transitioning to its first commercial implementation in H2 2026. Initial revenue is expected in Q4, representing a completely new service-based revenue stream outside of capital equipment budgets.
International Probe Sales Reversing
A massive divergence has emerged geographically. U.S. revenue accelerated to 57% YoY growth ($27.6M), while International revenue decelerated sharply, falling 14% YoY to $5.0M. Management cited decreased probe sales to international distributors. This structural weakness in overseas markets prevents total growth from being even higher.
Q3 Guidance Contradicts Q2 Profitability Run-Rate
Despite slashing the Adjusted EBITDA loss to just $1.4M in Q2, Q3 guidance calls for a loss of $6M-$9M. This implies that Q2 benefitted from lumpy licensing milestones that won't repeat linearly, or that management is aggressively ramping spend in Q3 for the Home Care and Embedded expansions.
Operating Expense Creep
Operating expenses accelerated, jumping 19% YoY to $37.0M. Even excluding stock-based compensation, expenses rose from $23.1M to $26.3M. Management points to headcount investments to support software and product development. While revenue growth currently outpaces expense growth, this creep threatens the timeline to sustained GAAP profitability.
Other KPIs
Accelerating significantly from 63.7% a year ago and 68.9% in Q1. The shift in product mix toward Butterfly Embedded licensing revenue and reduced legacy software amortization is proving that the semiconductor platform model yields software-like economics.
Stable. Down moderately from $150.5M at the end of FY25. With Adjusted EBITDA loss dropping to just $1.4M this quarter, the company's liquidity runway has dramatically extended, functionally eliminating near-term dilution risk if they maintain this execution.
Guidance
Accelerating. Raised from the prior $117-$121M view. The midpoint of $121M implies roughly 24% YoY growth, demonstrating management's high confidence in the back half of the year driven by Embedded and Home Care catalysts.
Accelerating. Improved from prior guidance of $(21) - $(25) million. With only ~$7.5M in EBITDA loss generated in H1 2026, this implies H2 2026 will see heavier losses ($11.5M - $15.5M), reflecting planned commercial launch investments.
Accelerating YoY. The midpoint of $28M represents a robust 30% YoY growth compared to Q3 2025's $21.5M, though it marks a sequential deceleration from the $32.6M achieved in Q2.
Decelerating sequentially. A stark step back from Q2's $(1.4)M loss, confirming that the path to sustainable profitability will experience lumpiness as investments are made and Embedded milestone payments fluctuate.
Key Questions
Margin Durability
Gross margins crossed 71% this quarter. How much of this was driven by one-time licensing milestones from Embedded partners, and what is the sustainable baseline margin expectation for the next 12 months?
International Weakness
With International revenue falling 14% YoY despite robust 57% U.S. growth, what is the root cause of the distributor pullback, and what interventions are planned to reverse this trend?
Sequential EBITDA Gap
Adjusted EBITDA loss was nearly wiped out at $1.4M in Q2, yet Q3 guidance expects a $6-$9M loss. Can you break down the specific OpEx investments or revenue timing driving this sequential step-back?